Several new candidates in HIV drug pipeline discussed at conference
This year's Conference on
Retroviruses and Opportunistic Infections (CROI 2017), held last month in Seattle,
included presentations on several new investigational antiretroviral drugs in
development, reflecting a more robust pipeline than we have seen in recent
Although modern antiretroviral therapy (ART) is highly
effective and well tolerated by most people living with HIV, having more
available drugs that work in different ways offers more options for putting
together optimal regimens.
Some of the experimental agents discussed at CROI
represent novel drug classes that work differently to existing
antiretrovirals, including capsid inhibitors in early studies and monoclonal antibodies now in late-stage human trials.
Other presentations focused
on next-generation candidates in familiar antiretroviral classes. Given that
widely used approved drugs are very effective for HIV treatment, researchers
are seeking incremental benefits in the areas of improved tolerability and
convenience – such as long-acting drugs – as well as new options for HIV
pre-exposure prophylaxis, or PrEP.